{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-141119","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2025-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.701879+00:00","generated_at":"2026-05-19T06:40:18.447607+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FDA Orange Book corrected; VOQUEZNA NCE exclusivity confirmed through May 2032","bullets":["FDA updated Orange Book to show full 10-year NCE exclusivity for VOQUEZNA (vonoprazan) 10 mg and 20 mg tablets.","Corrected listing confirms exclusivity runs through May 3, 2032, aligning with statutory requirements.","Phathom says this reinforces the long-term commercial runway for its first-in-class product.","NCE exclusivity prevents generic competition for the full 10-year period from approval date."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-141119","json":"https://secwatch.observer/filing/0001193125-25-141119.json","markdown":"https://secwatch.observer/filing/0001193125-25-141119.md","text":"https://secwatch.observer/filing/0001193125-25-141119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525141119/0001193125-25-141119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525141119/d924090d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T06:40:18.447607+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}